Jump to content

Ipidacrine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Edgar181 (talk | contribs) at 23:52, 11 April 2016. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Ipidacrine
Clinical data
Trade namesNeiromidin
Other namesAmiridine; NIK-247
ATC code
Legal status
Legal status
  • US: Not FDA approved; unscheduled
Identifiers
  • 2,3,5,6,7,8-Hexahydro-1H-cyclopenta[b]quinolin-9-amine
PubChem CID
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.201.385 Edit this at Wikidata
Chemical and physical data
FormulaC12H16N2
Molar mass188.27 g/mol g·mol−1
3D model (JSmol)
  • C1CCc2c(c(c3c(n2)CCC3)N)C1
  • InChI=1S/C12H16N2/c13-12-8-4-1-2-6-10(8)14-11-7-3-5-9(11)12/h1-7H2,(H2,13,14)
  • Key:YLUSMKAJIQOXPV-UHFFFAOYSA-N

Ipidacrine (Neiromidin) is a drug first synthesized by the National Research Center for Biologically Active Compounds in the Russian Federation. This compound is a derivative of 4-aminopyridine and is structurally similar to tacrine.[1]

Ipidacrine is a reversible acetylcholinesterase inhibitor used in memory disorders of different origins.[2][3][4]

Ipidacrine directly stimulates impulse transmission in the central nervous system and neuromuscular synapses by blocking membrane potassium channels. Ipidacrine enhances not only choline, but also adrenaline, serotonin, histamine, and oxytocin effects on smooth muscle.[5]

References

  1. ^ Kojima, Jun; Onodera, Kenji; Ozeki, Mitsuo; Nakayama, Kunio (1998). "Ipidacrine (NIK-247): A Review of Multiple Mechanisms as an Antidementia Agent". CNS Drug Reviews. 4 (3): 247. doi:10.1111/j.1527-3458.1998.tb00067.x.
  2. ^ Damulin, IV; Stepkina, DA; Lokshina, AB (2011). "Neuromidin in mixed vascular and Alzheimer's dementia". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 111 (2): 40–3. PMID 21350422.
  3. ^ Pustokhanova, LV; Morozova, EM (2011). "Cognitive disorders in the early rehabilitation period of ischemic stroke and possibilities of their treatment with neuromidin". Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova / Ministerstvo zdravookhraneniia i meditsinskoi promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe obshchestvo nevrologov \i] Vserossiiskoe obshchestvo psikhiatrov. 111 (4 Pt 2): 23–7. PMID 23120773.
  4. ^ Onodera, K; Kojima, J; Wachi, M (1998). "Ipidacrine (NIK-247), a novel antidementia, rapidly enters the brain and improves scopolamine-induced amnesia in rats during the Morris water maze task". Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. 18 (2): 33–7. PMID 9656230.
  5. ^ Neiromidin Product Information


Retrieved from "https://en.wikipedia.org/w/index.php?title=Ipidacrine&oldid=714808393"